---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-039602"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2026-10-14T20:25:43+00:00"
generated_at: "2026-10-14T20:27:03.741774+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Lisata Therapeutics expands board to 8, appoints Jeff Farrow as Class III director and audit committee member

## Summary
- Board voted October 13, 2026 to increase size from seven to eight members and appointed Jeffrey Farrow (age 65) to the newly created seat, effective immediately.
- Farrow's initial term expires at the 2028 annual meeting; he was also named to the Audit Committee and is independent under Nasdaq rules.
- Farrow is currently CFO and Chief Strategy Officer of Tarsus Pharmaceuticals (Nasdaq: TARS), a role held since April 2023.
- Prior roles: CFO of Global Blood Therapeutics through its Pfizer acquisition (2016-2022), CFO of ZS Pharma (acquired by AstraZeneca, 2015) and CFO of Hyperion Therapeutics (acquired by Horizon, 2015).
- CEO David Mazzo cited Farrow's financial discipline as Lisata advances Phase 2b programs in severe hypertriglyceridemia and acromegaly.

## SEC filing metadata
- accession: 0001140361-26-039602
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2026-10-14T20:25:43+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000114036126039602/0001140361-26-039602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000114036126039602/ef20083796_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-039602
- JSON: https://secwatch.observer/filing/0001140361-26-039602.json
- Plain text: https://secwatch.observer/filing/0001140361-26-039602.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.